100 results about "Mental dysfunction" patented technology

The invention discloses a mental disease classification method fusing prior knowledge and a multi-mode self-attention mechanism, and belongs to the technical field of medical image processing. In order to solve the problems that in the current mental disease classification process, biomarker information is dispersed, and reproducibility is insufficient, multi-mode nerve image data, field priori knowledge and the intelligent analysis ability of a large language model are fully fused, and existing mental disease biomarkers are integrated, optimized and utilized. And related medical knowledge is efficiently extracted and integrated by using a large language model, so that efficient and accurate classification of mental diseases is realized. The method provides an innovative technical path and theoretical support for precise diagnosis and mechanism research of mental disorders.

The invention provides a mental disorder aided decision-making method and system based on multi-modal data, and belongs to the technical field of disease aided decision-making, the method is applied to a system comprising a data acquisition module, a preliminary screening module and an aided decision-making module, and the method specifically comprises the following steps: preprocessing the multi-modal data of a patient; in combination with the mental disorder risk level of the patient of the preliminary screening model, decision assistance is triggered according to the mental disorder risk level, or corresponding decision suggestions are matched and output; when decision assistance is triggered, the disease classification probability and severity are obtained through a diagnosis model based on a cross-modal attention mechanism, meanwhile, according to a time-dependent risk prediction model, a survival probability curve of a recurrence risk is generated in combination with historical diagnosis data of a patient, and decision assistance suggestions are determined by integrating outputs of the two models. According to the method, on the basis of multi-modal data, multiple types of intelligent models are fused, objective data support is provided in the assessment and intervention process, and the missed diagnosis and misdiagnosis risks of mental disorders are reduced.

The invention discloses a juvenile depressive disorder diagnosis marker, a depressive disorder diagnosis model and application thereof, and relates to the technical field of mental disorder diagnosis. Adiponectin is applied to auxiliary diagnosis or diagnosis of adolescent depressive disorder, the AUC value of a diagnosis model is larger than 0.7, and the adiponectin is high in diagnosis sensitivity and specificity and can serve as a diagnosis or auxiliary diagnosis marker of adolescent depressive disorder. Adiponectin and other indexes are combined for detection, the diagnosis performance of auxiliary diagnosis of juvenile depressive disorder can be improved, and the method has a good clinical application prospect.

The present invention relates to novel compounds of Formula (I), wherein P, Q, A, B, m, n, R1, Z, J and L are defined as in Formula (I); which are gamma-(y)-aminobutyric acid type B receptor ("GABAB-R") positive allosteric modulators which are useful for the treatment or prevention of neurological and psychiatric disorders associated with GABA dysfunction and diseases in which the GABAB receptor is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes of preparing such compounds and such compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases in which GABAB-R is involved.

The present disclosure provides compounds of Formula (I), (II), and (III). The provided compounds are able to bind protein kinases (e.g., SIK) and may be useful in modulating (e.g., inhibiting) the activity of a protein kinase (e.g., SIK, (e.g., SIK1, SIK2, or SIK3)) in a subject or cell. The provided compounds may be useful in treating or preventing a disease (e.g., proliferative disease, musculoskeletal disease, genetic disease, hematological disease, neurological disease, painful condition, psychiatric disorder, or metabolic disorder) in a subject in need thereof. Also provided are pharmaceutical compositions, kits, methods, and uses that include or involve a compound described herein.

There is provided a computer implemented method of diagnosing a medical state associated with a neuro-psychiatric disorder in a subject, comprising: receiving a plurality of EEG datasets, each respective EEG dataset from a respective EEG electrode of a plurality of EEG electrodes monitoring a head of the subject, clustering the plurality of EEG datasets into a plurality of clusters, computing a p-adic representation of the plurality of clusters, extracting a quantum potential value from p-adic representation of the plurality of clusters, and diagnosing the medical state associated with the neuro-psychiatric disorder according to the quantum potential relative to a threshold that separates between presence of the medical state and non-presence of the medical state.

Disclosed are a wearable mental disorder automatic diagnosis system and a method based on contrastive learning. The system is realized by a wearable device and includes a data acquisition unit for obtaining multi-modal physiological data of a user; a user registration unit for executing the following steps under the condition that the user is determined to be a new user: fine-tuning a first feature encoder which is pre-trained offline by using the multi-mode physiological data in a self-supervised contrastive learning mode to obtain a second feature encoder; extracting data features from labeled multi-modal physiological data through a second feature encoder; training a personalized classifier using the data features as input to obtain a mental disorder recognition model; and a recognition unit for obtaining recognition results using the mental disorder recognition model when it is determined that the user is not a new user.

The invention discloses a task-driven fNIRS decoding neural feedback training method and a task-driven fNIRS decoding neural feedback training system, which are characterized in that an individualized decoder is constructed by utilizing task state fNIRS data in a pretest stage, and a preselected feature set with the strongest discriminating power is screened out, so that a stable brain activity mode highly related to a specific cognitive function is targeted to neural feedback training; therefore, a foundation is laid for realizing accurate nerve regulation and control; in a real-time training stage, the system continuously decodes the brain activity into a positive state instead of a negative state as a feedback index, so that a subject can induce a target neural mode through self-regulation without being exposed to external unfavorable stimulation completely, and the target neural mode can be used as a target neural mode. The training pertinence and nerve specificity of advanced cognitive functions such as interference control are enhanced, a closed-loop training mode based on data driving and an individualized model can be applied to treatment of psychological and mental disorders, and discomfort and risks possibly brought by a traditional exposure therapy are effectively avoided.

The invention discloses a dynamic trajectory construction and visual mapping method for association of mental disorder brain network damage and systemic system diseases, and belongs to the field of artificial intelligence medical application. According to the method, high-resolution MRI images, biomarkers and clinical information of major mental disorder patients are collected, and the influence of factors such as age, gender, medication and diagnosis on the braingut axis and the cardio-cerebral axis is evaluated through multi-modal data fusion. By constructing a disease dynamic trajectory model, brain structures and function change modes corresponding to different mental disorders are identified. Large-scale samples are analyzed through machine learning, potential risks and protection factors are extracted, and a visual tool is developed to visually display changes of the brain under different disease systems. A closed-loop feedback mechanism is established through follow-up visit, the disease progress and the intervention effect are dynamically tracked, and key evaluation indexes are identified. According to the invention, theoretical basis and practical guidance are provided for early screening, precise intervention and personalized treatment of mental disorders, and the diagnosis and treatment accuracy and efficiency are remarkably improved.

This invention relates to the finding that testis development related protein (TDRP; also termed Immuno-moodulin or Imood herein) is a circulatory anxiogenic factor that modulates anxiety-like behaviour in mammalian models through the regulation of the immune system. Methods of treatment of mental disorders, such as anxiety, and TDRP antagonists for use in such methods are provided. Methods of diagnosing or monitoring a mental disorder in an individual by determining levels of TDRP in a sample and methods of screening for compounds that reduce levels of TDRP are provided.

A brain information display device and a brain information display method are provided that can help a user identify a mental disorder by utilizing the association between a mental disorder and a brain region associated with the mental disorder. [Solution] The brain information display device 1 comprises a brain region display unit 22 that displays brain regions within the brain separately, a case information acquisition unit 23 that acquires case information on the brain region for the mental illness, an evaluation unit 24 that assigns an evaluation value to the brain region in the brain region display unit based on the case information acquired by the case information acquisition unit, and an association display unit 25 that displays the association between the mental illness and the brain region that produces symptoms associated with the mental illness based on the evaluation value assigned by the evaluation unit.

The present invention relates to novel compounds of Formula (I'), wherein P, Q, A, B, m, n, R1, R2, R9, R10, R11 and R12 are defined as in Formula (I'). These compounds may be useful as muscarinic M4 receptor subtype ("M4-mAChR") positive allosteric modulators which are useful for the treatment or prevention of neurological and psychiatric disorders associated with muscarinic M4 receptor dysfunction and diseases in which the M4 receptor is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes of preparing such compounds and such compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases such as for example, cognitive decline, both positive and negative symptoms in schizophrenia as well as other disorders modulated by M4 muscarinic receptors.

The present disclosure includes azetidine tryptamines and methods of treating psychiatric disorders with such compounds. Also provided are pharmaceutical compositions comprising azetidine tryptamine.

Novel compositions of N-desmethyl ruboxistaurin L-lactate salt and L-lactate salt polymorphs. The use of compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs to modulate GSK-3 signaling is disclosed, as is the use of compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs to inhibit protein kinase C. Methods are also disclosed of using compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs in the treatment of subjects having a neurological disease and / or psychiatric disorder, including Alzheimer's disease, bipolar disorder, depression, schizophrenia, Parkinson's disease, or neuroinflammation, as well as methods of using compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs in treating conditions associated with diabetes mellitus or its complications, or ischemia, inflammation, pulmonary hypertension, congestive heart failure, cardiovascular disease, dermatological disease, or cancer. In addition, compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs administered in combination with lithium or other treatments for bipolar disorder are also disclosed.

The invention relates to application of broad bean pyrimidine in preparation of antidepressant drugs, and belongs to the technical field of biological medicines. Depression is a common and high-disability heavy mental disorder, has the core characteristics of remarkable and lasting emotion lowering and interest loss, seriously damages the social functions and life quality of patients, and has become one of the major public health burdens in the world. Based on new cognition of complex mechanisms of diseases, a new generation of antidepressant drugs which have a brand new action mechanism, can more accurately intervene in core pathological links of the diseases and can better meet the clinical requirements are researched and developed, and the new generation of antidepressant drugs are not only an inevitable direction for promoting psychopharmacology progress, but also are urgent medical necessities for improving prognosis of hundreds of millions of patients and relieving social burdens. A per2- / -mutant zebrafish depression model is used for performing drug screening on traditional Chinese medicine monomers, and finally it is found that 10 mM of broad bean pyrimidine has the anti-depression characteristic and can effectively improve the depression-like phenotype of per2- / -mutant zebrafish.

The present invention relates to macrocyclic urea compounds that are orexin receptor agonists. The present invention also relates to the use of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases involving the orexin receptors. The present invention also relates to compositions containing these compounds. The present invention also relates to the use of these compositions in the potential prevention or treatment of such diseases involving the orexin receptors.

The present disclosure provides systems and methods relating to brain stimulation therapy. In particular, the present disclosure provides systems and methods for identifying effective stimulation patterns for reducing one or more symptoms or a neurological or psychiatric disorder.

The present invention relates to combinations, combinations for use, methods of treatment, kits, dosing regimens, delivery devices, adjunctive treatment methods, short-acting psychedelic agents for use, or parenteral formulations for use, for treating mental disorders in patients. In particular, the present invention relates to administering short-acting psychedelic agents in combination with monoamine antidepressants, such as selective serotonin reuptake inhibitors (SSRIs).

The present disclosure includes azetidinyl tryptamines and methods of using such compounds to treat psychiatric disorders. Also provided are pharmaceutical compositions comprising azetidinyl tryptamines.

In one embodiment of the present invention, the present invention relates to a pharmaceutical composition for treating an individual having a disorder selected from communication disorders, motor impairments, cognitive impairments, mental disorders, sensory disorders, autism spectrum disorders, and pervasive developmental disorders, the pharmaceutical composition comprising L-serine or a pharmaceutically acceptable salt thereof.

Indazole compounds which are useful as allosteric potentiators / positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease states associated with glutamate dysfunction.

This application discloses the use of ritonavir or its derivatives in the preparation of medicaments for treating mental disorders. This application also discloses the discovery of mice (AtLAS) with difficulty in extinction of fear memories. ‑ / ‑ Intraperitoneal injection of ritonavir significantly restored the rigidity rate in model mice. Further immunoblotting and co-precipitation confirmed that ritonavir could significantly block the binding of Syn2a and Syngr-3, and promote the formation of VAMP2, Syntaxin, and SNAP25 trimers, thereby promoting the normal release of presynaptic membrane vesicles in neurons and restoring the rigidity rate in mice with refractory rigidity, thus achieving the treatment of mental disorders such as post-traumatic stress disorder.

Provided herein are methods and compositions for treating neurological diseases (e.g., neurodegenerative disorders (e.g., Alzheimer's disease, Parkinson's disease, dementia, a tauopathy, chronic traumatic encephalopathy (CTE), traumatic brain injury (TBI), mild cognitive impairment); psychiatric disorders (e.g., bipolar disorder, schizophrenia, depression, anxiety, post-traumatic stress disorder, obsessive compulsive disorder); inflammation in the central nervous system) using lithium salts, activators that increase the expression or activity of the RE1 silencing transcription factor (REST), or a combination thereof, or in combination with an additional agent.

The present invention relates to 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use in treating a patient who has been diagnosed with a mental disorder or a nervous system disorder by administration of a 5-MeO-DMT / salt treatment course. The 5-MeO-DMT / salt treatment course involves administration of one or more doses of 5-MeO-DMT or a pharmaceutically acceptable salt thereof on a single day to remove or alleviate one or more symptoms of the mental disorder or the nervous system disorder. The patient is also treated with one or more antidepressant(s).

Deuterium-labeled 4-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)oxy)piperidines substituted with pyrrolo[3,4-b]pyridin-5-one, furo[3,4-b]pyridin-5(7H)-one, or [1,2,4]triazolo[4,3-a]pyrimidin-3(2H)-one are positive allosteric modulators of the muscarinic acetylcholine receptor M4 (mAChR M4) and may have use in treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction.

Disclosed are a method and a system for the assessment of the severity of a psychiatric disorder (PD) using measurements of computational and high-order functions in brain organoid neurons.

The invention relates to an anti-depression compound 4-methyl-6-methoxy coumarin, and belongs to the technical field of biological medicines. Depression is the most common mental disorder in the world and is also a main reason for disability. The development of a novel anti-depression drug which is based on a nerve plasticity mechanism, takes effect quickly, has a lasting curative effect and is high in safety, and particularly has important clinical requirements and technical necessity for an effective treatment means for refractory depression. Traditional Chinese medicine monomers and a per2- / -zebra fish depression model are adopted for anti-depression drug screening, and finally it is found that 10 mM of 4-methyl-6-methoxycoumarin has the anti-depression characteristic and has the positive treatment effect on the exploration behavior, social interaction and sleep-awakening period of per2- / -zebra fish. The method can effectively rescue and reverse depression-like phenotypes observed in a per2- / -zebra fish circadian rhythmic depression model, and can restore the balance of important gene expression.

The present invention relates to an apparatus for the neuropsychological evaluation and rehabilitation of mental disorders. The apparatus comprises a ramp (1) positioned in the sagittal plane, with a forward stimulation screen (3) at both ends of the ramp equipped with a fixed isosceles trapezoidal spectacle bridge (2) and various visual stimulation means (8, 18-25). Between the ends of the ramp (1) are arranged a forward filter screen (5) equipped with one or more forward bars or forward half-bars (4) that slide on the ramp according to a scale ruler and mathematical form (11-17), various visual stimulation filtering means (9, 26-30), and a forward hybrid screen (6) equipped with various visual stimulation means and visual stimulation filtering means (10). The apparatus is supported by legs (7) and is movable across all planes in space. The use of the apparatus also includes evaluation steps (31-37) and evaluation processes (38-52).

The invention discloses a pulse generator for electric spasm treatment and a control method thereof, and relates to the technical field of medical electronics. The pulse generator comprises a medical power supply, an energy storage capacitor bank, a full-bridge converter, a pulse transformer, an electrode port, a charging circuit, a current control circuit, a pulse width limiting circuit, a detection circuit and a microcontroller; the charging circuit adjusts energy storage voltage according to treatment voltage or patient impedance, and the energy storage capacitor bank adopts safe extra-low voltage energy storage; the current control circuit realizes constant current output through proportional integral control, the pulse width limiting circuit limits the maximum pulse width through hardware, and each key module has electrical isolation. The scheme solves the problems of difficult current control and large side effect of the existing equipment, improves the stability of the treatment current and the safety of the equipment, and is suitable for the electric spasm treatment of mental disorders such as depression.

This invention discloses a pleiotropic gene sharing genetic structure with obesity and mental disorders, along with its screening method and applications, belonging to the field of biomedical technology. The pleiotropic gene includes RERE, NEGR1, DENND1B, CTNNB1, TMEM106B, SP4, TSNARE1, DENND1A, CNNM2, NT5C2, BMAL1, MPHOSPH9, CCDC92, YLPM1, TAOK2, RTN4RL1, and ARFGEF2. The process includes collecting GWAS summary statistics on obesity-related phenotypes and mental disorders, assessing genetic correlation, screening pleiotropic genetic loci and candidate pleiotropic genes, using TWAS to screen pleiotropic genes, functional analysis and drug target prediction, and bidirectional causal association genetic validation. These methods are used to prepare drugs for the treatment of obesity and mental disorders or to construct a risk prediction model for obesity-mental disorder comorbidity.